Brüss M, Bönisch H, Göthert M, Molderings G J
Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstrasse 2b, 53113 Bonn, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):328-31. doi: 10.1007/s00210-003-0698-3. Epub 2003 Feb 14.
In view of the high structural and pharmacological similarities between the alpha(2A)-adrenoceptors of humans and other mammalian species, it has been concluded, in particular, from experiments in rabbits that the (2A)-adrenoceptor is the exclusive site of action of central antihypertensive drugs, although the amino acid sequence of the alpha(2A)-adrenoceptor of just this species was unknown. Therefore, the aim of the present investigation was to determine the complete nucleotide sequence of the coding region of the rabbit alpha(2A)-adrenoceptor gene. Degenerate oligonucleotides corresponding to regions of the alpha(2A)-adrenoceptor conserved between rat and man were used in a polymerase chain reaction with genomic DNA prepared from rabbit. A 1,356-base pair product with an open reading frame of 1,353 base pairs was obtained that encodes a protein of 451 amino acids which is similar to the alpha(2A)-adrenoceptors of other mammals (man, pig, rat, mouse, guinea-pig and cattle) but not to their alpha(2B)- and alpha(2C)-adrenoceptor subtypes suggesting its classification as an alpha(2A)-adrenoceptor. However, the degree of amino acid sequence identity is, at best, only 80% and, thus, about 10% less than between the other mammalian species. Compared with the human sequence there are 81 substantial changes of amino acids. In conclusion, rabbit and human alpha(2A)-adrenoceptors substantially differ in their amino acid sequence which may explain the opposite pharmacodynamic properties of the central antihypertensive drug rilmenidine (alpha(2)-adrenoceptor agonism and antagonism, respectively) reported in the literature. Hence, the present study supports the view that experiments with central antihypertensive drugs in rabbits are not reliably predictive for the site of action of such drugs in man.
鉴于人类与其他哺乳动物物种的α(2A)-肾上腺素能受体在结构和药理学上具有高度相似性,尤其从兔子实验得出结论,即(2A)-肾上腺素能受体是中枢性抗高血压药物的唯一作用位点,尽管当时仅该物种的α(2A)-肾上腺素能受体的氨基酸序列尚不清楚。因此,本研究的目的是确定兔α(2A)-肾上腺素能受体基因编码区的完整核苷酸序列。与大鼠和人之间保守的α(2A)-肾上腺素能受体区域相对应的简并寡核苷酸,用于与从兔子制备的基因组DNA进行聚合酶链反应。获得了一个1356个碱基对的产物,其开放阅读框为1353个碱基对,编码一个451个氨基酸的蛋白质,该蛋白质与其他哺乳动物(人、猪、大鼠、小鼠、豚鼠和牛)的α(2A)-肾上腺素能受体相似,但与它们的α(2B)-和α(2C)-肾上腺素能受体亚型不同,表明其可归类为α(2A)-肾上腺素能受体。然而,氨基酸序列同一性程度最高仅为80%,因此比其他哺乳动物物种之间约少10%。与人类序列相比,有81个氨基酸的实质性变化。总之,兔和人α(2A)-肾上腺素能受体在氨基酸序列上有很大差异,这可能解释了文献中报道的中枢性抗高血压药物利美尼定(分别为α(2)-肾上腺素能受体激动和拮抗)相反的药效学特性。因此,本研究支持这样一种观点,即兔子中枢性抗高血压药物实验不能可靠地预测此类药物在人体内的作用位点。